chr10-100152322-T-G
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_006459.4(ERLIN1):āc.856A>Cā(p.Lys286Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000298 in 1,613,148 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Consequence
NM_006459.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ERLIN1 | NM_006459.4 | c.856A>C | p.Lys286Gln | missense_variant | 11/11 | ENST00000421367.7 | NP_006450.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ERLIN1 | ENST00000421367.7 | c.856A>C | p.Lys286Gln | missense_variant | 11/11 | 1 | NM_006459.4 | ENSP00000410964 | P1 | |
ERLIN1 | ENST00000407654.7 | c.856A>C | p.Lys286Gln | missense_variant | 12/12 | 1 | ENSP00000384900 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152196Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000677 AC: 17AN: 251018Hom.: 0 AF XY: 0.0000295 AC XY: 4AN XY: 135694
GnomAD4 exome AF: 0.0000301 AC: 44AN: 1460952Hom.: 0 Cov.: 31 AF XY: 0.0000248 AC XY: 18AN XY: 726806
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152196Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74356
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 22, 2022 | The c.856A>C (p.K286Q) alteration is located in exon 11 (coding exon 11) of the ERLIN1 gene. This alteration results from a A to C substitution at nucleotide position 856, causing the lysine (K) at amino acid position 286 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Hereditary spastic paraplegia 62 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 14, 2021 | This sequence change replaces lysine with glutamine at codon 286 of the ERLIN1 protein (p.Lys286Gln). The lysine residue is moderately conserved and there is a small physicochemical difference between lysine and glutamine. This variant is present in population databases (rs774243081, ExAC 0.01%). This variant has not been reported in the literature in individuals affected with ERLIN1-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at